Published in Vasc Health Risk Manag on July 25, 2013
Are Endothelial Progenitor Cells the Real Solution for Cardiovascular Diseases? Focus on Controversies and Perspectives. Biomed Res Int (2015) 0.79
Selective inactivation of NADPH oxidase 2 causes regression of vascularization and the size and stability of atherosclerotic plaques. Atherosclerosis (2015) 0.78
Cholesterol: A modulator of the phagocyte NADPH oxidase activity - A cell-free study. Redox Biol (2014) 0.78
Impaired compensation to femoral artery ligation in diet-induced obese mice is primarily mediated via suppression of collateral growth by Nox2 and p47phox. Am J Physiol Heart Circ Physiol (2015) 0.78
Pathophysiology and Treatments of Oxidative Injury in Ischemic Stroke: Focus on the Phagocytic NADPH Oxidase 2. Antioxid Redox Signal (2014) 0.77
The Importance of NADPH Oxidases and Redox Signaling in Angiogenesis. Antioxidants (Basel) (2017) 0.76
Elevated peripheral blood mononuclear cell-derived superoxide production in healthy young black men. Am J Physiol Heart Circ Physiol (2014) 0.76
NOX4 downregulation leads to senescence of human vascular smooth muscle cells. Oncotarget (2016) 0.75
CD38 mediates angiotensin II-induced intracellular Ca(2+) release in rat pulmonary arterial smooth muscle cells. Am J Respir Cell Mol Biol (2015) 0.75
Nox Inhibitors & Therapies: Rational Design of Peptidic and Small Molecule Inhibitors. Curr Pharm Des (2015) 0.75
The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev (2007) 21.13
Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res (2000) 10.95
NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res (2000) 8.62
Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res (1994) 8.57
Redox regulation of fos and jun DNA-binding activity in vitro. Science (1990) 7.09
FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol (2000) 6.54
Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant. Hypertension (2007) 5.80
Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest (2005) 5.53
Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol Cell (2002) 5.41
Signal transduction by reactive oxygen species. J Cell Biol (2011) 5.21
Distinct subcellular localizations of Nox1 and Nox4 in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol (2003) 4.56
Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ Res (2007) 4.48
Nox4 is a protective reactive oxygen species generating vascular NADPH oxidase. Circ Res (2012) 4.19
Reversible inactivation of protein-tyrosine phosphatase 1B in A431 cells stimulated with epidermal growth factor. J Biol Chem (1998) 4.05
Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation (2002) 3.95
NOX4 activity is determined by mRNA levels and reveals a unique pattern of ROS generation. Biochem J (2007) 3.88
Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes (2006) 3.85
Role of oxidative stress in cardiovascular diseases. J Hypertens (2000) 3.73
The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med (1995) 3.60
Hypoxia-dependent regulation of nonphagocytic NADPH oxidase subunit NOX4 in the pulmonary vasculature. Circ Res (2007) 3.28
Oxidative stress and gene regulation. Free Radic Biol Med (2000) 3.24
Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O(2)(-) and systolic blood pressure in mice. Circ Res (2001) 3.24
Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. Am J Respir Cell Mol Biol (1994) 3.23
Activation of integrins in endothelial cells by fluid shear stress mediates Rho-dependent cytoskeletal alignment. EMBO J (2001) 3.22
Nox4 is required for maintenance of the differentiated vascular smooth muscle cell phenotype. Arterioscler Thromb Vasc Biol (2006) 3.13
Regulation of ROS signal transduction by NADPH oxidase 4 localization. J Cell Biol (2008) 3.13
Nox1 overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. Circulation (2005) 3.12
Studies on the inhibitory mechanism of iodonium compounds with special reference to neutrophil NADPH oxidase. Biochem J (1993) 3.12
Upregulation of Nox-based NAD(P)H oxidases in restenosis after carotid injury. Arterioscler Thromb Vasc Biol (2002) 3.10
Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov (2011) 3.08
NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart. Proc Natl Acad Sci U S A (2010) 2.95
Poldip2, a novel regulator of Nox4 and cytoskeletal integrity in vascular smooth muscle cells. Circ Res (2009) 2.83
NADPH oxidases: functions and pathologies in the vasculature. Arterioscler Thromb Vasc Biol (2009) 2.83
Nox1 is involved in angiotensin II-mediated hypertension: a study in Nox1-deficient mice. Circulation (2005) 2.79
Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration. PLoS Biol (2010) 2.72
NADPH oxidase is the primary source of superoxide induced by NMDA receptor activation. Nat Neurosci (2009) 2.71
Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol (1998) 2.71
Role of NADH/NADPH oxidase-derived H2O2 in angiotensin II-induced vascular hypertrophy. Hypertension (1998) 2.70
Distinct roles of Nox1 and Nox4 in basal and angiotensin II-stimulated superoxide and hydrogen peroxide production. Free Radic Biol Med (2008) 2.68
ICAM-1-mediated, Src- and Pyk2-dependent vascular endothelial cadherin tyrosine phosphorylation is required for leukocyte transendothelial migration. J Immunol (2007) 2.66
Lipid raft clustering and redox signaling platform formation in coronary arterial endothelial cells. Hypertension (2005) 2.62
Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation (2002) 2.57
Endothelial cell-to-cell junctions. FASEB J (1995) 2.56
Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res (2002) 2.56
Retracted Novel role of gp91(phox)-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis. Circ Res (2002) 2.56
A Ca(2+)-activated NADPH oxidase in testis, spleen, and lymph nodes. J Biol Chem (2001) 2.56
p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J Biol Chem (1996) 2.56
Mechanotransduction in response to shear stress. Roles of receptor tyrosine kinases, integrins, and Shc. J Biol Chem (1999) 2.51
Contrasting roles of NADPH oxidase isoforms in pressure-overload versus angiotensin II-induced cardiac hypertrophy. Circ Res (2003) 2.50
Nuclear and mitochondrial compartmentation of oxidative stress and redox signaling. Annu Rev Pharmacol Toxicol (2006) 2.48
Cytokine activation of nuclear factor kappa B in vascular smooth muscle cells requires signaling endosomes containing Nox1 and ClC-3. Circ Res (2007) 2.47
Endothelial Nox4 NADPH oxidase enhances vasodilatation and reduces blood pressure in vivo. Arterioscler Thromb Vasc Biol (2011) 2.44
Calcium-dependent NOX5 nicotinamide adenine dinucleotide phosphate oxidase contributes to vascular oxidative stress in human coronary artery disease. J Am Coll Cardiol (2008) 2.44
Two novel proteins activate superoxide generation by the NADPH oxidase NOX1. J Biol Chem (2002) 2.41
NAD(P)H oxidase Nox-4 mediates 7-ketocholesterol-induced endoplasmic reticulum stress and apoptosis in human aortic smooth muscle cells. Mol Cell Biol (2004) 2.38
The superoxide-producing NAD(P)H oxidase Nox4 in the nucleus of human vascular endothelial cells. Genes Cells (2005) 2.38
NADPH oxidase-4 mediates protection against chronic load-induced stress in mouse hearts by enhancing angiogenesis. Proc Natl Acad Sci U S A (2010) 2.36
Expression and localization of NOX2 and NOX4 in primary human endothelial cells. Antioxid Redox Signal (2005) 2.32
Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am J Physiol Cell Physiol (2001) 2.28
Nox2-derived radicals contribute to neurovascular and behavioral dysfunction in mice overexpressing the amyloid precursor protein. Proc Natl Acad Sci U S A (2008) 2.27
Redox control of endothelial function and dysfunction: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal (2008) 2.24
Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension (2002) 2.20
The E-loop is involved in hydrogen peroxide formation by the NADPH oxidase Nox4. J Biol Chem (2011) 2.20
Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. Cancer Res (1993) 2.18
IQGAP proteins are integral components of cytoskeletal regulation. EMBO Rep (2003) 2.17
Compartmentalization of redox signaling through NADPH oxidase-derived ROS. Antioxid Redox Signal (2009) 2.17
Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ Res (2000) 2.15
Ischemic stroke injury is reduced in mice lacking a functional NADPH oxidase. Stroke (1997) 2.14
NADPH oxidase plays a central role in blood-brain barrier damage in experimental stroke. Stroke (2007) 2.13
Nox2 and Rac1 regulate H2O2-dependent recruitment of TRAF6 to endosomal interleukin-1 receptor complexes. Mol Cell Biol (2006) 2.12
Decreased blood pressure in NOX1-deficient mice. FEBS Lett (2005) 2.10
Intracellular localization and preassembly of the NADPH oxidase complex in cultured endothelial cells. J Biol Chem (2002) 2.05
VE-PTP and VE-cadherin ectodomains interact to facilitate regulation of phosphorylation and cell contacts. EMBO J (2002) 2.05
Inhibition of NADPH oxidase is neuroprotective after ischemia-reperfusion. J Cereb Blood Flow Metab (2009) 2.02
Direct evidence of a role for Nox2 in superoxide production, reduced nitric oxide bioavailability, and early atherosclerotic plaque formation in ApoE-/- mice. Am J Physiol Heart Circ Physiol (2009) 2.00
Reactive oxygen species as downstream mediators of angiogenic signaling by vascular endothelial growth factor receptor-2/KDR. J Biol Chem (2001) 1.95
Novel mechanism of activation of NADPH oxidase 5. calcium sensitization via phosphorylation. J Biol Chem (2006) 1.90
Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol (2002) 1.89
Mechanical stretch enhances mRNA expression and proenzyme release of matrix metalloproteinase-2 (MMP-2) via NAD(P)H oxidase-derived reactive oxygen species. Circ Res (2003) 1.86
IQGAP1, a novel vascular endothelial growth factor receptor binding protein, is involved in reactive oxygen species--dependent endothelial migration and proliferation. Circ Res (2004) 1.85
NOX2 and NOX4 mediate proliferative response in endothelial cells. Antioxid Redox Signal (2006) 1.83
Vascular NAD(P)H oxidase activation in diabetes: a double-edged sword in redox signalling. Cardiovasc Res (2009) 1.82
Priming of the neutrophil NADPH oxidase activation: role of p47phox phosphorylation and NOX2 mobilization to the plasma membrane. Semin Immunopathol (2008) 1.81
Small-molecule NOX inhibitors: ROS-generating NADPH oxidases as therapeutic targets. Antioxid Redox Signal (2009) 1.80
Subcellular targeting of oxidants during endothelial cell migration. J Cell Biol (2005) 1.79
A novel role for epidermal growth factor receptor tyrosine kinase and its downstream endoplasmic reticulum stress in cardiac damage and microvascular dysfunction in type 1 diabetes mellitus. Hypertension (2012) 1.78
Critical role of the NAD(P)H oxidase subunit p47phox for left ventricular remodeling/dysfunction and survival after myocardial infarction. Circ Res (2007) 1.77
gp91phox-containing NADPH oxidase mediates endothelial dysfunction in renovascular hypertension. Circulation (2004) 1.77
First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis. J Med Chem (2010) 1.74
The contribution of Nox4 to NADPH oxidase activity in mouse vascular smooth muscle. Cardiovasc Res (2005) 1.72
Reactive oxygen species mediate Rac-induced loss of cell-cell adhesion in primary human endothelial cells. J Cell Sci (2002) 1.72
Targeting and regulation of reactive oxygen species generation by Nox family NADPH oxidases. Antioxid Redox Signal (2009) 1.71
Nox4-derived H2O2 mediates endoplasmic reticulum signaling through local Ras activation. Mol Cell Biol (2010) 1.69
Fulvene-5 potently inhibits NADPH oxidase 4 and blocks the growth of endothelial tumors in mice. J Clin Invest (2009) 1.68
Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan. Hypertension (2007) 1.68
Mineralocorticoid receptor blockade improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarction. Hypertension (2007) 1.68
Involvement of Nox2 NADPH oxidase in adverse cardiac remodeling after myocardial infarction. Hypertension (2008) 1.68
Comparative pharmacology of chemically distinct NADPH oxidase inhibitors. Br J Pharmacol (2010) 1.67
NADPH oxidase activity and function are profoundly greater in cerebral versus systemic arteries. Circ Res (2005) 1.65
Validation of the GRACE risk score for predicting death within 6 months of follow-up in a contemporary cohort of patients with acute coronary syndrome. Rev Esp Cardiol (2010) 2.78
[Clinical features and prognosis of patients with chronic cerebrovascular disease (ICBAR study)]. Rev Neurol (2011) 2.57
[Hemodynamic effects of levosimendan compared with dobutamine in patients with low cardiac output after cardiac surgery]. Rev Esp Cardiol (2006) 2.26
Cardiac troponin I and creatine kinase MB isoenzyme in patients with chronic renal failure. Nefrologia (2012) 1.96
Growth hormone releasing peptide (ghrelin) is synthesized and secreted by cardiomyocytes. Cardiovasc Res (2004) 1.60
Adiponectin is synthesized and secreted by human and murine cardiomyocytes. FEBS Lett (2005) 1.58
Impact of new criteria for anticoagulant treatment in atrial fibrillation. Rev Esp Cardiol (2011) 1.44
[Renal failure is an independent predictor of mortality in hospitalized heart failure patients and is associated with a worse cardiovascular risk profile]. Rev Esp Cardiol (2006) 1.42
Prevalence of chronic kidney disease in patients with or at a high risk of cardiovascular disease. Rev Esp Cardiol (2010) 1.41
Influence of the preimplantation QRS axis on responses to cardiac resynchronization therapy. Rev Esp Cardiol (2008) 1.40
[Pneumopericardium complicating bronchogenic carcinoma]. Rev Esp Cardiol (2002) 1.06
Effects of hydrazine derivatives on vascular smooth muscle contractility, blood pressure and cGMP production in rats: comparison with hydralazine. Vascul Pharmacol (2003) 1.04
Effects of cis-resveratrol on inflammatory murine macrophages: antioxidant activity and down-regulation of inflammatory genes. J Leukoc Biol (2004) 1.00
[Diabetes mellitus in cardiology practice in Spain. Survey by the Working Group on Heart and Diabetes regarding the importance of diabetes mellitus in relation with other cardiovascular diseases]. Rev Esp Cardiol (2004) 1.00
The possible implication of trans-Resveratrol in the cardioprotective effects of long-term moderate wine consumption. Mol Pharmacol (2002) 0.99
Soluble receptor of advanced glycation end products levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients, independent of advanced glycation end products levels: New Roles for Soluble RAGE. Eur J Heart Fail (2010) 0.99
Glycated albumin, a precursor of advanced glycation end-products, up-regulates NADPH oxidase and enhances oxidative stress in human endothelial cells: molecular correlate of diabetic vasculopathy. Diabetes Metab Res Rev (2010) 0.96
Effects of trans- and cis-resveratrol on Ca2+ handling in A7r5 vascular myocytes. Eur J Pharmacol (2007) 0.94
Implication of cyclic nucleotide phosphodiesterase inhibition in the vasorelaxant activity of the citrus-fruits flavonoid (+/-)-naringenin. Planta Med (2005) 0.94
Pravastatin counteracts angiotensin II-induced upregulation and activation of NADPH oxidase at plasma membrane of human endothelial cells. J Cardiovasc Pharmacol (2010) 0.93
[Gender differences in adiponectin and leptin expression in epicardial and subcutaneous adipose tissue. Findings in patients undergoing cardiac surgery]. Rev Esp Cardiol (2006) 0.89
Coronary artery disease is associated with higher epicardial retinol-binding protein 4 (RBP4) and lower glucose transporter (GLUT) 4 levels in epicardial and subcutaneous adipose tissue. Clin Endocrinol (Oxf) (2012) 0.89
Des-acyl ghrelin has specific binding sites and different metabolic effects from ghrelin in cardiomyocytes. Endocrinology (2010) 0.88
Comparative study of the vasorelaxant activity, superoxide-scavenging ability and cyclic nucleotide phosphodiesterase-inhibitory effects of hesperetin and hesperidin. Naunyn Schmiedebergs Arch Pharmacol (2004) 0.88
Morbidity and mortality among heart failure patients in Galicia, N.W. Spain: the GALICAP Study. Int J Cardiol (2008) 0.88
In vitro effects of mangiferin on superoxide concentrations and expression of the inducible nitric oxide synthase, tumour necrosis factor-alpha and transforming growth factor-beta genes. Biochem Pharmacol (2003) 0.86
Left ventricular mass regression after aortic valve replacement with the new Mitroflow 12A pericardial bioprosthesis. J Heart Valve Dis (2006) 0.86
Predictive value of advanced glycation end products for the development of post-infarction heart failure: a preliminary report. Cardiovasc Diabetol (2012) 0.85
Leptin does not induce hypertrophy, cell cycle alterations, or production of MCP-1 in cultured rat and mouse cardiomyocytes. Endocr Res (2005) 0.84
[Comparison of coronary risk estimates derived using the Framingham and REGICOR equations]. Rev Esp Cardiol (2005) 0.83
Non-genomic vasorelaxant effects of 17β-estradiol and progesterone in rat aorta are mediated by L-type Ca2+ current inhibition. Acta Pharmacol Sin (2012) 0.83
Adiponectin and p53 mRNA in epicardial and subcutaneous fat from heart failure patients. Eur J Clin Invest (2013) 0.82
Potassium channels are involved in testosterone-induced vasorelaxation of human umbilical artery. Naunyn Schmiedebergs Arch Pharmacol (2007) 0.82
Evidence for a role of advanced glycation end products in atrial fibrillation. Int J Cardiol (2011) 0.82
[Influence of sex on mortality in hospitalized patients with congestive heart failure and preserved or depressed systolic function]. Rev Esp Cardiol (2005) 0.81
PDE4 and PDE5 regulate cyclic nucleotides relaxing effects in human umbilical arteries. Eur J Pharmacol (2007) 0.81
Infective endocarditis due to Streptococcus bovis in a series of nonaddict patients: clinical and morphological characteristics of 20 cases and review of the literature. Can J Cardiol (2003) 0.81
Influence of heart failure on nucleolar organization and protein expression in human hearts. Biochem Biophys Res Commun (2012) 0.81
[Factors associated with uncontrolled hypertension in patients with and without cardiovascular disease]. Rev Esp Cardiol (2011) 0.81
Relation of soluble receptor for advanced glycation end products to predict mortality in patients with chronic heart failure independently of Seattle Heart Failure Score. Am J Cardiol (2011) 0.80
Procyanidins from grape pomace are suitable inhibitors of human endothelial NADPH oxidase. J Cell Biochem (2012) 0.80
Antioxidant activity and inhibitory effects of hydralazine on inducible NOS/COX-2 gene and protein expression in rat peritoneal macrophages. Int Immunopharmacol (2004) 0.79
Trends in clinical profile and medical treatments of atrial fibrillation patients over the last 10 years. Rev Port Cardiol (2013) 0.79
Diagnostic value of N-terminal pro-brain natriuretic peptide in pleural effusions of cardiac origin. Arch Bronconeumol (2011) 0.79
Evaluation of a multiplex real-time PCR assay for detecting pathogens in cardiac valve tissue in patients with endocarditis. Rev Esp Cardiol (2010) 0.79
Fluorescent advanced glycation end products and their soluble receptor: the birth of new plasmatic biomarkers for risk stratification of acute coronary syndrome. PLoS One (2013) 0.78
Percutaneous coronary intervention in a patient with a CoreValve aortic valve prosthesis. Rev Esp Cardiol (2010) 0.78
BleeMACS: rationale and design of the study. J Cardiovasc Med (Hagerstown) (2016) 0.78
Hydralazine decreases sodium nitroprusside-induced rat aortic ring relaxation and increased cGMP production by rat aortic myocytes. Life Sci (2005) 0.77
Statins modulate feedback regulation mechanisms between advanced glycation end-products and C-reactive protein: evidence in patients with acute myocardial infarction. Eur J Pharm Sci (2013) 0.77
[Global treatment of cardiovascular risk in the hypertensive patient]. Rev Esp Cardiol (2007) 0.77
Short-term metabolic changes achieved by weight loss in hypertensive patients. Int J Cardiol (2010) 0.76
[Ankle brachial index and cardiovascular risk]. Med Clin (Barc) (2003) 0.76
[Dyslipemia in diabetics treated with statins. Results of the DYSIS study in Spian]. Med Clin (Barc) (2012) 0.76
Effect of diabetes on the clinical characteristics and prognosis of patients with chronic ischemic heart disease. The CIBAR study. Rev Esp Cardiol (2010) 0.76
Sex does not influence prognosis in diabetic patients. The Barbanza Diabetes study. Rev Esp Cardiol (2010) 0.76
Cystatin C provides more information than other renal function parameters for stratifying risk in patients with acute coronary syndrome. Rev Esp Cardiol (2009) 0.76
Diagnostic accuracy of computer-assisted electrocardiography in the diagnosis of left ventricular hypertrophy in left bundle branch block. Rev Esp Cardiol (Engl Ed) (2011) 0.76
Letter by Raposeiras-Roubin et al regarding article, "mortality associated with atrial fibrillation in patients with myocardial infarction: a systematic review and meta-analysis". Circulation (2011) 0.75
Acute hyperglycemia: is really a new risk marker for contrast-induced nephropathy in patients with acute myocardial infarction without diabetes and normal renal function? Am Heart J (2011) 0.75
Assessment of long-term quality of life after cavotricuspid isthmus ablation for typical atrial flutter. Health Qual Life Outcomes (2014) 0.75
Advanced glycation end products: a mysterious shadow beyond the relationship between HbA1c and atrial fibrillation. Int J Cardiol (2012) 0.75
Postoperative left ventricular thrombosis and transthoracic echocardiography: is it enough? Crit Care (2011) 0.75
Two reflections about Amadori products: biomarkers or therapeutic targets for coronary artery disease?. Cardiology (2012) 0.75
Response to the comment on "Cardiac troponin I and creatine kinase MB isoenzyme in patients with chronic renal failure". Nefrologia (2013) 0.75
Is glycated hemoglobin an accurate enough predictor of subclinical myocardial injury or a simple precursor of advanced glycation end products? J Am Coll Cardiol (2012) 0.75
[Ignoring familiar decision for increasing organ donations?]. Med Clin (Barc) (2006) 0.75
[Impact of concomitant use of P2Y12 inhibitors and proton pump inhibitors on ischemia events in patients with acute coronary syndrome in real world]. Zhonghua Yi Xue Za Zhi (2016) 0.75
[Blood pressure control in hypertensive patients with left ventricular hypertrophy. The VIIDA Study]. Rev Esp Cardiol (2007) 0.75
Therapeutic management of emphysematous pancreatitis. Rev Esp Enferm Dig (2011) 0.75
[Not Available]. Rev Esp Cardiol (2010) 0.75
[Galician study of heart failure in primary care (GALICAP Study)]. Rev Esp Cardiol (2007) 0.75
[Beyond blood pressure reduction in the treatment of arterial hypertension. Clinical implications of the LIFE study]. Rev Esp Cardiol (2002) 0.75
Structural and functional inverse cardiac remodeling after cavotricuspid isthmus ablation in patients with typical atrial flutter. Rev Esp Cardiol (Engl Ed) (2012) 0.75
[Advanced glycation end-products: new markers of renal dysfunction in patients with chronic heart failure]. Med Clin (Barc) (2011) 0.75
[Cardiovascular disease and hypertensive cardiomyopathy. Beyond heart]. Med Clin (Barc) (2006) 0.75
[Aldosterone blockade in heart failure. So much for so little]. Med Clin (Barc) (2002) 0.75
Prognostic impact of atrial fibrillation progression in a community study: AFBAR Study (Atrial Fibrillation in the Barbanza Area Study). Int J Cardiol (2010) 0.75
Advanced glycation end-products as long-term predictors of death and reinfarction after an acute coronary syndrome. Biomark Med (2015) 0.75
[Hypertensive heart disease: a proposed clinical classification]. Rev Esp Cardiol (2006) 0.75
[Changes in lipid profile after regular intake of canned fish. The influence of addition of isoflavones, omega-3 fatty acids and fitosterols]. Med Clin (Barc) (2007) 0.75
Importance of recognizing occult renal disease in hypertensive patients. Rev Esp Cardiol (2009) 0.75
Risk Scores From PARIS Registry: Are They Useful in a Contemporary Cohort of ACS Patients? J Am Coll Cardiol (2016) 0.75
[Long-term trends in drug prescription for hospitalized patients with congestive heart failure. Influence of type of dysfunction]. Rev Esp Cardiol (2005) 0.75
Left bundle branch block in atrial fibrillation patients without heart failure. Int J Cardiol (2013) 0.75